{"id":15701,"date":"2023-03-12T19:22:19","date_gmt":"2023-03-12T19:22:19","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=15701"},"modified":"2023-03-15T20:51:15","modified_gmt":"2023-03-15T20:51:15","slug":"%ce%b7-%cf%80%cf%81%cf%8e%cf%84%ce%b7-%ce%b5%ce%b3%ce%ba%ce%b5%ce%ba%cf%81%ce%b9%ce%bc%ce%ad%ce%bd%ce%b7-%ce%b8%ce%b5%cf%81%ce%b1%cf%80%ce%b5%ce%af%ce%b1-%ce%b3%ce%b9%ce%b1-%cf%84%ce%bf-%cf%83%cf%8d","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/el\/%ce%b7-%cf%80%cf%81%cf%8e%cf%84%ce%b7-%ce%b5%ce%b3%ce%ba%ce%b5%ce%ba%cf%81%ce%b9%ce%bc%ce%ad%ce%bd%ce%b7-%ce%b8%ce%b5%cf%81%ce%b1%cf%80%ce%b5%ce%af%ce%b1-%ce%b3%ce%b9%ce%b1-%cf%84%ce%bf-%cf%83%cf%8d\/","title":{"rendered":"\u03a0\u03c1\u03ce\u03c4\u03b7 \u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03bf \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett: \u03bc\u03b9\u03b1 \u03c0\u03b9\u03b8\u03b1\u03bd\u03ae \u03b5\u03bb\u03c0\u03af\u03b4\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03bf\u03c5\u03c2 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03b4\u03b9\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03bf\u03cd \u03c4\u03bf\u03c5 MECP2;"},"content":{"rendered":"

\u0397 10\u03b7 \u039c\u03b1\u03c1\u03c4\u03af\u03bf\u03c5 2023 \u03bf\u03c1\u03af\u03b6\u03b5\u03b9 \u03bc\u03b9\u03b1 \u03c0\u03bf\u03bb\u03cd \u03c3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ae \u03b7\u03bc\u03b5\u03c1\u03bf\u03bc\u03b7\u03bd\u03af\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03b7\u03bd \u03ba\u03bf\u03b9\u03bd\u03cc\u03c4\u03b7\u03c4\u03b1 \u03c4\u03c9\u03bd \u03c3\u03c0\u03ac\u03bd\u03b9\u03c9\u03bd \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03b9\u03ce\u03bd.<\/p>\n\n\n\n

\u0397 \u03c4\u03c1\u03bf\u03c6\u03b9\u03bd\u03b5\u03c4\u03af\u03b4\u03b7 \u03ad\u03c7\u03b5\u03b9 \u03b5\u03b3\u03ba\u03c1\u03b9\u03b8\u03b5\u03af \u03b1\u03c0\u03cc \u03c4\u03bf FDA \u03b3\u03b9\u03b1 \u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b1\u03c3\u03b8\u03b5\u03bd\u03ce\u03bd \u03bc\u03b5 \u03a3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett<\/a>\u03ba\u03b1\u03b8\u03b9\u03c3\u03c4\u03ce\u03bd\u03c4\u03b1\u03c2 \u03c4\u03bf \u03c4\u03b7\u03bd \u03c0\u03c1\u03ce\u03c4\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03bf \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett. \u03a4\u03bf \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf, \u03c4\u03bf \u03bf\u03c0\u03bf\u03af\u03bf \u03ba\u03c5\u03ba\u03bb\u03bf\u03c6\u03bf\u03c1\u03b5\u03af \u03c3\u03c4\u03b7\u03bd \u03b1\u03b3\u03bf\u03c1\u03ac \u03bc\u03b5 \u03c4\u03b7\u03bd \u03bf\u03bd\u03bf\u03bc\u03b1\u03c3\u03af\u03b1 Daybue\u2122, \u03b1\u03bd\u03b1\u03bc\u03ad\u03bd\u03b5\u03c4\u03b1\u03b9 \u03bd\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b5\u03bc\u03c0\u03bf\u03c1\u03b9\u03ba\u03ac \u03b4\u03b9\u03b1\u03b8\u03ad\u03c3\u03b9\u03bc\u03bf \u03c3\u03c4\u03b9\u03c2 \u0397\u03a0\u0391 \u03ad\u03c9\u03c2 \u03c4\u03b1 \u03c4\u03ad\u03bb\u03b7 \u0391\u03c0\u03c1\u03b9\u03bb\u03af\u03bf\u03c5 2023 \u03b3\u03b9\u03b1 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03b7\u03bb\u03b9\u03ba\u03af\u03b1\u03c2 \u03ac\u03bd\u03c9 \u03c4\u03c9\u03bd 2 \u03b5\u03c4\u03ce\u03bd.<\/p>\n\n\n\n

\u0397 \u03c4\u03c1\u03bf\u03c6\u03b9\u03bd\u03b5\u03c4\u03af\u03b4\u03b7 \u03b5\u03af\u03bd\u03b1\u03b9 \u03ad\u03bd\u03b1 \u03c4\u03c1\u03b9\u03c0\u03b5\u03c0\u03c4\u03af\u03b4\u03b9\u03bf \u03c0\u03bf\u03c5 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03bc\u03b9\u03b1 \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 \u03c0\u03bf\u03c5 \u03bf\u03bd\u03bf\u03bc\u03ac\u03b6\u03b5\u03c4\u03b1\u03b9 \u03b9\u03bd\u03c3\u03bf\u03c5\u03bb\u03b9\u03bd\u03bf\u03b5\u03b9\u03b4\u03ae\u03c2 \u03b1\u03c5\u03be\u03b7\u03c4\u03b9\u03ba\u03cc\u03c2 \u03c0\u03b1\u03c1\u03ac\u03b3\u03bf\u03bd\u03c4\u03b1\u03c2 1 (IGF-1). \u039c\u03c0\u03bf\u03c1\u03b5\u03af \u03bd\u03b1 \u03c7\u03bf\u03c1\u03b7\u03b3\u03b7\u03b8\u03b5\u03af \u03b1\u03c0\u03cc \u03c4\u03bf \u03c3\u03c4\u03cc\u03bc\u03b1. \u0391\u03c5\u03c4\u03cc \u03c4\u03bf \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf \u03b8\u03b5\u03c9\u03c1\u03b5\u03af\u03c4\u03b1\u03b9 \u03cc\u03c4\u03b9 \u03bc\u03b5\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03b7 \u03c6\u03bb\u03b5\u03b3\u03bc\u03bf\u03bd\u03ae \u03ba\u03b1\u03b9 \u03b2\u03b5\u03bb\u03c4\u03b9\u03ce\u03bd\u03b5\u03b9 \u03c4\u03b7\u03bd \u03b5\u03c0\u03b9\u03ba\u03bf\u03b9\u03bd\u03c9\u03bd\u03af\u03b1 \u03bc\u03b5\u03c4\u03b1\u03be\u03cd \u03c4\u03c9\u03bd \u03bd\u03b5\u03c5\u03c1\u03ce\u03bd\u03c9\u03bd \u03c3\u03c4\u03bf\u03bd \u03b5\u03b3\u03ba\u03ad\u03c6\u03b1\u03bb\u03bf, \u03b7 \u03bf\u03c0\u03bf\u03af\u03b1 \u03b5\u03af\u03bd\u03b1\u03b9 \u03b4\u03b9\u03b1\u03c4\u03b1\u03c1\u03b1\u03b3\u03bc\u03ad\u03bd\u03b7 \u03c3\u03c4\u03b1 \u03ac\u03c4\u03bf\u03bc\u03b1 \u03bc\u03b5 \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett. \u039a\u03bb\u03b9\u03bd\u03b9\u03ba\u03ad\u03c2 \u03b4\u03bf\u03ba\u03b9\u03bc\u03ad\u03c2 \u03c6\u03ac\u03c3\u03b7\u03c2 \u0399\u0399\u0399 \u03ad\u03c7\u03bf\u03c5\u03bd \u03b4\u03b5\u03af\u03be\u03b5\u03b9 \u03cc\u03c4\u03b9 \u03b7 \u03c4\u03c1\u03bf\u03c6\u03b9\u03bd\u03ad\u03c4\u03b9\u03b4\u03b7 \u03b2\u03b5\u03bb\u03c4\u03b9\u03ce\u03bd\u03b5\u03b9 \u03b4\u03b9\u03ac\u03c6\u03bf\u03c1\u03b1 \u03c3\u03c5\u03bc\u03c0\u03c4\u03ce\u03bc\u03b1\u03c4\u03b1 \u03c4\u03bf\u03c5 \u03c3\u03c5\u03bd\u03b4\u03c1\u03cc\u03bc\u03bf\u03c5 Rett, \u03cc\u03c0\u03c9\u03c2 \u03b7 \u03b2\u03b5\u03bb\u03c4\u03af\u03c9\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03ba\u03bf\u03b9\u03bd\u03c9\u03bd\u03b9\u03ba\u03ae\u03c2 \u03b5\u03c0\u03b9\u03ba\u03bf\u03b9\u03bd\u03c9\u03bd\u03af\u03b1\u03c2, \u03c4\u03b7\u03c2 \u03c3\u03c5\u03bc\u03c0\u03b5\u03c1\u03b9\u03c6\u03bf\u03c1\u03ac\u03c2 \u03ba\u03b1\u03b9 \u03c4\u03b7\u03c2 \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1\u03c2 \u03c4\u03c9\u03bd \u03c7\u03b5\u03c1\u03b9\u03ce\u03bd.<\/p>\n\n\n\n

\n
\u0394\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03b7\u03bd Acadia<\/a><\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

\u0395\u03bd\u03ce \u03b7 \u03c5\u03c0\u03bf\u03ba\u03b5\u03af\u03bc\u03b5\u03bd\u03b7 \u03b3\u03b5\u03bd\u03b5\u03c4\u03b9\u03ba\u03ae \u03b1\u03b9\u03c4\u03af\u03b1 \u03c4\u03bf\u03c5 \u03c3\u03c5\u03bd\u03b4\u03c1\u03cc\u03bc\u03bf\u03c5 \u03b4\u03b9\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03bf\u03cd \u03c4\u03bf\u03c5 MECP2 (MDS) \u03b5\u03af\u03bd\u03b1\u03b9 \u03b4\u03b9\u03b1\u03c6\u03bf\u03c1\u03b5\u03c4\u03b9\u03ba\u03ae \u03b1\u03c0\u03cc \u03b5\u03ba\u03b5\u03af\u03bd\u03b7 \u03c4\u03bf\u03c5 \u03a3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett<\/a>\u039a\u03b1\u03b9 \u03bf\u03b9 \u03b4\u03cd\u03bf \u03b4\u03b9\u03b1\u03c4\u03b1\u03c1\u03b1\u03c7\u03ad\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03bc\u03b5\u03c4\u03ac\u03bb\u03bb\u03b1\u03be\u03b7 \u03c3\u03c4\u03bf \u03b3\u03bf\u03bd\u03af\u03b4\u03b9\u03bf MECP2. \u03a4\u03bf \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett \u03c0\u03c1\u03bf\u03c3\u03b2\u03ac\u03bb\u03bb\u03b5\u03b9 \u03ba\u03c5\u03c1\u03af\u03c9\u03c2 \u03ba\u03bf\u03c1\u03af\u03c4\u03c3\u03b9\u03b1 \u03ba\u03b1\u03b9 \u03ad\u03c7\u03b5\u03b9 \u03c0\u03bf\u03bb\u03cd \u03bb\u03af\u03b3\u03b7 \u03b5\u03bd\u03b5\u03c1\u03b3\u03ae \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7 MeCP2, \u03b5\u03bd\u03ce \u03c4\u03bf \u039c\u0394\u03a3, \u03c0\u03bf\u03c5 \u03b4\u03b9\u03b1\u03b3\u03b9\u03b3\u03bd\u03ce\u03c3\u03ba\u03b5\u03c4\u03b1\u03b9 \u03ba\u03c5\u03c1\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b1\u03b3\u03cc\u03c1\u03b9\u03b1, \u03bf\u03b4\u03b7\u03b3\u03b5\u03af \u03c3\u03b5 \u03c5\u03c8\u03b7\u03bb\u03cc\u03c4\u03b5\u03c1\u03b1 \u03b5\u03c0\u03af\u03c0\u03b5\u03b4\u03b1 \u03c4\u03b7\u03c2 \u03c0\u03c1\u03c9\u03c4\u03b5\u0390\u03bd\u03b7\u03c2. \u0395\u03af\u03bd\u03b1\u03b9 \u03b5\u03bd\u03b4\u03b9\u03b1\u03c6\u03ad\u03c1\u03bf\u03bd \u03cc\u03c4\u03b9 \u03c4\u03cc\u03c3\u03bf \u03c4\u03bf Rett \u03cc\u03c3\u03bf \u03ba\u03b1\u03b9 \u03c4\u03bf MDS \u03c0\u03c1\u03bf\u03ba\u03b1\u03bb\u03bf\u03cd\u03bd \u03bc\u03b5\u03b9\u03c9\u03bc\u03ad\u03bd\u03b7 \u03b1\u03bd\u03ac\u03c0\u03c4\u03c5\u03be\u03b7 \u03ba\u03b1\u03b9 \u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1 \u03c4\u03bf\u03c5 \u03b5\u03b3\u03ba\u03b5\u03c6\u03ac\u03bb\u03bf\u03c5, \u03bc\u03b5 \u03b1\u03c0\u03bf\u03c4\u03ad\u03bb\u03b5\u03c3\u03bc\u03b1 \u03c0\u03b1\u03c1\u03cc\u03bc\u03bf\u03b9\u03b1 \u03c3\u03c5\u03bc\u03c0\u03c4\u03ce\u03bc\u03b1\u03c4\u03b1, \u03cc\u03c0\u03c9\u03c2 \u03b4\u03b9\u03b1\u03bd\u03bf\u03b7\u03c4\u03b9\u03ba\u03ae \u03b1\u03bd\u03b1\u03c0\u03b7\u03c1\u03af\u03b1, \u03c0\u03c1\u03bf\u03b2\u03bb\u03ae\u03bc\u03b1\u03c4\u03b1 \u03c3\u03c5\u03bd\u03c4\u03bf\u03bd\u03b9\u03c3\u03bc\u03bf\u03cd \u03ba\u03b1\u03b9 \u03b5\u03c0\u03b9\u03bb\u03b7\u03c0\u03c4\u03b9\u03ba\u03ad\u03c2 \u03ba\u03c1\u03af\u03c3\u03b5\u03b9\u03c2.<\/p>\n\n\n\n

\u03a9\u03c2 \u03b5\u03ba \u03c4\u03bf\u03cd\u03c4\u03bf\u03c5, \u03bf\u03b9 \u03b5\u03c0\u03b9\u03c3\u03c4\u03b7\u03bc\u03bf\u03bd\u03b9\u03ba\u03ad\u03c2 \u03b5\u03be\u03b5\u03bb\u03af\u03be\u03b5\u03b9\u03c2 \u03c3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ac \u03bc\u03b5 \u03c4\u03bf \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett \u03c3\u03c5\u03bc\u03b2\u03ac\u03bb\u03bb\u03bf\u03c5\u03bd \u03c3\u03c4\u03b7\u03bd \u03b1\u03cd\u03be\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03b3\u03bd\u03ce\u03c3\u03b7\u03c2 \u03b3\u03b9\u03b1 \u03c4\u03b1 \u03ac\u03bb\u03bb\u03b1 \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03b1. \u0397 \u03ad\u03b3\u03ba\u03c1\u03b9\u03c3\u03b7 \u03c4\u03bf\u03c5 Daybue\u2122 \u03b1\u03bd\u03bf\u03af\u03b3\u03b5\u03b9 \u03c4\u03b7\u03bd \u03c0\u03cc\u03c1\u03c4\u03b1 \u03b3\u03b9\u03b1 \u03c0\u03b5\u03c1\u03b1\u03b9\u03c4\u03ad\u03c1\u03c9 \u03ad\u03c1\u03b5\u03c5\u03bd\u03b1 \u03c3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ac \u03bc\u03b5 \u03c4\u03b7 \u03c7\u03c1\u03ae\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03c4\u03c1\u03bf\u03c6\u03b9\u03bd\u03b5\u03c4\u03af\u03b4\u03b7\u03c2 \u03c3\u03b5 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03b4\u03b9\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03bf\u03cd \u03c4\u03bf\u03c5 MECP2.<\/p>\n\n\n\n

\u039f \u03b1\u03b3\u03ce\u03bd\u03b1\u03c2 \u03b4\u03b5\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c4\u03b5\u03bb\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9 \u03b3\u03b9\u03b1 \u03c4\u03bf \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03b4\u03b9\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03bf\u03cd \u03c4\u03bf\u03c5 MECP2. \u03a3\u03c5\u03bc\u03b2\u03ac\u03bb\u03bb\u03b5\u03c4\u03b5 \u03c3\u03c4\u03b7\u03bd \u03c0\u03c1\u03bf\u03ce\u03b8\u03b7\u03c3\u03b7 \u03c4\u03b7\u03c2 \u03ad\u03c1\u03b5\u03c5\u03bd\u03b1\u03c2 \u03b3\u03b9\u03b1 \u03bc\u03b9\u03b1 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03c4\u03bf\u03c5 MDS \u03bc\u03b5 \u03b4\u03c9\u03c1\u03b5\u03ad\u03c2, \u03b5\u03c5\u03b1\u03b9\u03c3\u03b8\u03b7\u03c4\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03b3\u03b9\u03b1 \u03c4\u03bf \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03ba\u03b1\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03c3\u03c4\u03b9\u03c2 \u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03bc\u03b1\u03c2!<\/p>\n\n\n\n

\n
\u03a3\u03c5\u03bc\u03bc\u03b5\u03c4\u03ad\u03c7\u03b5\u03c4\u03b5 \u03c3\u03c4\u03bf\u03bd \u03b1\u03b3\u03ce\u03bd\u03b1 \u03bc\u03b1\u03c2!<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

The 10th of March 2023 sets a very important date in the rare disease community. Trofinetide has been approved by the FDA for treatment of patients with Rett Syndrome, making […]<\/p>","protected":false},"author":1,"featured_media":15703,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[87],"tags":[],"class_list":["post-15701","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\nFirst approved treatment for Rett syndrome: a potential hope for patients with MECP2 duplication syndrome? - DupMECP2<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/el\/\u03b7-\u03c0\u03c1\u03ce\u03c4\u03b7-\u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7-\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1-\u03b3\u03b9\u03b1-\u03c4\u03bf-\u03c3\u03cd\/?lang=en\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First approved treatment for Rett syndrome: a potential hope for patients with MECP2 duplication syndrome? - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"The 10th of March 2023 sets a very important date in the rare disease community. Trofinetide has been approved by the FDA for treatment of patients with Rett Syndrome, making […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/el\/\u03b7-\u03c0\u03c1\u03ce\u03c4\u03b7-\u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7-\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1-\u03b3\u03b9\u03b1-\u03c4\u03bf-\u03c3\u03cd\/?lang=en\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-12T19:22:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-15T20:51:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"First approved treatment for Rett syndrome: a potential hope for patients with MECP2 duplication syndrome?\",\"datePublished\":\"2023-03-12T19:22:19+00:00\",\"dateModified\":\"2023-03-15T20:51:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en\"},\"wordCount\":291,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"el\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en\",\"url\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en\",\"name\":\"First approved treatment for Rett syndrome: a potential hope for patients with MECP2 duplication syndrome? - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\",\"datePublished\":\"2023-03-12T19:22:19+00:00\",\"dateModified\":\"2023-03-15T20:51:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/dupmecp2.eu\/category\/news\/?lang=en\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"First approved treatment for Rett syndrome: a potential hope for patients with MECP2 duplication syndrome?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/el\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u03a0\u03c1\u03ce\u03c4\u03b7 \u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03bf \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett: \u03bc\u03b9\u03b1 \u03c0\u03b9\u03b8\u03b1\u03bd\u03ae \u03b5\u03bb\u03c0\u03af\u03b4\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03bf\u03c5\u03c2 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03b4\u03b9\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03bf\u03cd \u03c4\u03bf\u03c5 MECP2; - DupMECP2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/el\/\u03b7-\u03c0\u03c1\u03ce\u03c4\u03b7-\u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7-\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1-\u03b3\u03b9\u03b1-\u03c4\u03bf-\u03c3\u03cd\/?lang=en","og_locale":"el_GR","og_type":"article","og_title":"First approved treatment for Rett syndrome: a potential hope for patients with MECP2 duplication syndrome? - DupMECP2","og_description":"The 10th of March 2023 sets a very important date in the rare disease community. Trofinetide has been approved by the FDA for treatment of patients with Rett Syndrome, making […]","og_url":"https:\/\/dupmecp2.eu\/el\/\u03b7-\u03c0\u03c1\u03ce\u03c4\u03b7-\u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7-\u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1-\u03b3\u03b9\u03b1-\u03c4\u03bf-\u03c3\u03cd\/?lang=en","og_site_name":"DupMECP2","article_published_time":"2023-03-12T19:22:19+00:00","article_modified_time":"2023-03-15T20:51:15+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"Caroline","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"2 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"First approved treatment for Rett syndrome: a potential hope for patients with MECP2 duplication syndrome?","datePublished":"2023-03-12T19:22:19+00:00","dateModified":"2023-03-15T20:51:15+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en"},"wordCount":291,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","articleSection":["News"],"inLanguage":"el"},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en","url":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en","name":"\u03a0\u03c1\u03ce\u03c4\u03b7 \u03b5\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b7 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03bf \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf Rett: \u03bc\u03b9\u03b1 \u03c0\u03b9\u03b8\u03b1\u03bd\u03ae \u03b5\u03bb\u03c0\u03af\u03b4\u03b1 \u03b3\u03b9\u03b1 \u03c4\u03bf\u03c5\u03c2 \u03b1\u03c3\u03b8\u03b5\u03bd\u03b5\u03af\u03c2 \u03bc\u03b5 \u03c3\u03cd\u03bd\u03b4\u03c1\u03bf\u03bc\u03bf \u03b4\u03b9\u03c0\u03bb\u03b1\u03c3\u03b9\u03b1\u03c3\u03bc\u03bf\u03cd \u03c4\u03bf\u03c5 MECP2; - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","datePublished":"2023-03-12T19:22:19+00:00","dateModified":"2023-03-15T20:51:15+00:00","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/03\/FDA-approval-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/first-approved-treatment-for-rett-syndrome-a-potential-hope-for-patients-with-mecp2-duplication-syndrome\/?lang=en#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/dupmecp2.eu\/category\/news\/?lang=en"},{"@type":"ListItem","position":3,"name":"First approved treatment for Rett syndrome: a potential hope for patients with MECP2 duplication syndrome?"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"\u0395\u0395","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"\u039a\u03b1\u03c1\u03bf\u03bb\u03af\u03bd\u03b1","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/el\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/posts\/15701","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/comments?post=15701"}],"version-history":[{"count":0,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/posts\/15701\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/media\/15703"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/media?parent=15701"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/categories?post=15701"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/el\/wp-json\/wp\/v2\/tags?post=15701"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}